Dabrafenib and/or Trametinib Rollover Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.

NCT Number	NCT03340506
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
Enrollment	100 participants
Start Date	2018-01-26
Primary Completion	2032-12-28 (estimated)
Study Completion	2032-12-28 (estimated)
Updated on ClinicalTrials.gov	2026-07-09